Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

Summary

RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving lenalidomide together with cetuximab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with cetuximab in treating patients with metastatic colorectal cancer.

Timeline

Start

2009-10

Primary completion

2010-11

Completion

2010-12

Outcome

Outcome not reported

Stopped (Enrollment): “low accrual,loss of funding and results from EU study showing drug ineffective.”

Drugs

Indications